Facilitations and Hurdles of Genetic Testing in Neuromuscular Disorders
Open Access
- 14 April 2021
- journal article
- review article
- Published by MDPI AG in Diagnostics
- Vol. 11 (4) , 701
Abstract
Neuromuscular disorders (NMDs) comprise a heterogeneous group of disorders that affect about one in every thousand individuals worldwide. The vast majority of NMDs has a genetic cause, with about 600 genes already identified. Application of genetic testing in NMDs can be useful for several reasons: correct diagnostic definition of a proband, extensive familial counselling to identify subjects at risk, and prenatal diagnosis to prevent the recurrence of the disease; furthermore, identification of specific genetic mutations still remains mandatory in some cases for clinical trial enrollment where new gene therapies are now approaching. Even though genetic analysis is catching on in the neuromuscular field, pitfalls and hurdles still remain and they should be taken into account by clinicians, as for example the use of next generation sequencing (NGS) where many single nucleotide variants of “unknown significance” can emerge, complicating the correct interpretation of genotype-phenotype relationship. Finally, when all efforts in terms of molecular analysis have been carried on, a portion of patients affected by NMDs still remain “not genetically defined”. In the present review we analyze the evolution of genetic techniques, from Sanger sequencing to NGS, and we discuss “facilitations and hurdles” of genetic testing which must always be balanced by clinicians, in order to ensure a correct diagnostic definition, but taking always into account the benefit that the patient could obtain especially in terms of “therapeutic offer”.Keywords
This publication has 107 references indexed in Scilit:
- Current scenario of the genetic testing for rare neurological disorders exploiting next generation sequencingNeural Regeneration Research, 2020
- Diagnostic journey in Spinal Muscular Atrophy: Is it still an odyssey?PLOS ONE, 2020
- Facioscapulohumeral muscular dystrophy (FSHD) molecular diagnosis: from traditional technology to the NGS eraneurogenetics, 2019
- Genetic and genomic testing for neurologic disease in clinical practice2018
- Diagnosis of Duchenne Muscular Dystrophy in Italy in the last decade: Critical issues and areas for improvementsNeuromuscular Disorders, 2017
- Next-generation sequencing in neuromuscular diseasesCurrent Opinion in Neurology, 2016
- Neuromuscular disorders: genes, genetic counseling and therapeutic trialsGenetics and Molecular Biology, 2016
- Advances in genetic diagnosis of neurological disordersActa Neurologica Scandinavica, 2014
- New Insights About the Incidence, Multisystem Manifestations, and Care of Patients with Congenital Myotonic DystrophyThe Journal of Pediatrics, 2013
- Diagnostic odyssey of patients with myotonic dystrophyJournal of Neurology, 2013